Compare BETR & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BETR | TOI |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | 641 |
| Industry | Finance: Consumer Services | Medical/Nursing Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.9M | 512.9M |
| IPO Year | N/A | N/A |
| Metric | BETR | TOI |
|---|---|---|
| Price | $28.60 | $5.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $40.00 | $6.67 |
| AVG Volume (30 Days) | 309.2K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.02 | $30.15 |
| Revenue Next Year | $65.66 | $25.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.57 | $2.32 |
| 52 Week High | $94.06 | $5.82 |
| Indicator | BETR | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 52.36 | 56.69 |
| Support Level | $28.46 | $3.24 |
| Resistance Level | $29.98 | $5.54 |
| Average True Range (ATR) | 2.59 | 0.33 |
| MACD | 0.54 | -0.01 |
| Stochastic Oscillator | 58.89 | 41.30 |
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.